FCFernando Camacho

Fernando Camacho

*This is an algorithmically generated author record based on publicly available information.

Fernando Camacho has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lanzamiento y características de nuevos productos de vegetación de LSA SAF: el Data Record EPS VEGA-R

    by Adrián Jiménez-Guisado, F. Javier García-Haro, Manuel Campos-Taberner, Beatriz Martínez, Sergio Sánchez-Ruiz, María Amparo Gilabert, Fernando Camacho, Jorge Sánchez-Zapero, Enrique Martínez-Sánchez

    El Satellite Application Facility on Land Surface Analysis (LSA SAF) de EUMETSAT proporciona variables clave para la caracterización y monitorización de los ecosistemas terrestres. Este trabajo presenta los avances recientes en los productos globales de vegetación derivados del sensor AVHRR a bordo del EUMETSAT Polar System (EPS), con especial énfasis en el nuevo Data Record (DR) EPS VEGA-R, que cubre el periodo 2007-2021. Combinado con los productos operacionales en tiempo real (NRT), este conjunto permite disponer de una serie continua hasta la actualidad. Se describe la metodología empleada en su generación y su consistencia con los productos NRT, lo que posibilita su uso conjunto en estudios climáticos de largo plazo. Mediante el análisis de un episodio de sequía extrema en el Cuerno de África (2010-2011), se demuestra la capacidad de estos productos para capturar y describir patrones espaciales y temporales en la dinámica de la vegetación y en la evolución de la actividad fotosintética a escala regional y global.

  • Open Access

    GEOV2: Improved smoothed and gap filled time series of LAI, FAPAR and FCover 1 km Copernicus Global Land products

    by Aleixandre Verger, Jorge Sánchez-Zapero, Marie Weiss, Adrià Descals, Fernando Camacho, Roselyne Lacaze, Frédéric Baret


  • Open Access

    LSA SAF: a long-term service of vegetation variables for modelling terrestrial ecosystems at regional and global scales

    by Francisco Javier García-Haro, Manuel Campos-Taberner, Beatriz Martínez, Sergio Sánchez-Ruiz, Fernando Camacho, María Amparo Gilabert

    SPIE Digital Library Proceedings


  • Open Access

    A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

    by Michael Sebag, Nizar Bahlis, Christopher P. Venner, Arleigh McCurdy, C. Tom Kouroukis, Jesse Shustik, Darrell J White, Rami Kotb, Julie Stakiw, Nicole B. Laferriere, et al.

    Introduction As lenalidomide (Len) has become an integral part of therapy for newly diagnosed MM patients, most will have been either exposed or refractory to Len at the time of first or second relapse. The monoclonal antibody, Daratumumab, in combination with the more potent IMID pomalidomide (Pom) demonstrates good responses in patients previously exposed to lenalidomide. Low dose weekly cyclophosphamide has been shown to enhance the potency of pomalidomide in association with dexamethasone. In this clinical trial, we set out to compare the combination of daratumumab, weekly low dose cyclophosphamide, dexamethasone and pomalidomide (DCdP) to daratumumab, cyclophosphamide and dexamethasone (DCd) with pomalidomide added only at disease progression. Although we expected that a four-drug regiment would give superior clinical results, we hypothesized that a significant number of patients would not necessarily need all four drugs but could benefit from the addition of pomalidomide at treatment failure. Patients/Methods In this phase II clinical trial 120 patients with relapsed refractory myeloma, after at least one line of therapy, were randomized to receive either daratumumab (16mg/kg) weekly IV C1-2, every 2 weeks C3-6, monthly C7+, dexamethasone 40mg po weekly, cyclophosphamide 400mg po weekly and pomalidomide 4mg po days 1-21 of 28 day cycles (Arm A) or the same doses and dosing regimen of daratumumab, cyclophosphamide and dexamethasone but with pomalidomide added only after confirmed disease progression (Arm B). All patients had to be exposed to proteasome inhibitors and len prior to study entry. The primary endpoint of this study is the comparison of the PFS of Arm A and the PFS of Arm B after the addition Pom (PFS2) at 36 months while secondary endpoints included overall responses, duration of responses, survival and safety. Correlative laboratory studies are also planned. Results As of 1 April 2019 all 120 patients have been enrolled in 11 sites across Canada. The patient characteristics were: median age 65 (range 39-82); median 2 prior lines of therapy (range 1-8); 70% had a previous ASCT; 95% lenalidomide exposed; 93% proteasome inhibitor exposed; 90% lenalidomide and PI exposed; 25% carfilzomib exposed, len was the last line of therapy in 65%. Median follow-up was 8.2 months (range 1-15.6), median number of cycles 8 (range 1-17). The overall response rates (ORR) were 88.5% for arm A compared with 50.8% for arm B, with 57.4% and 25.4% of patients achieving ≥VGPR in arm A and B respectively. Among the 20 patients in Arm B that had progressed by data cutoff, the ORR after adding pomalidomide was 40% albeit with the short follow up time of 3.4 months. Although the median PFS of Arm A has not yet been reached, it was 10.9 mo. in Arm B prior to the addition of pom and 14.3 mo. from trial entry in the smaller group in whom pom was added after first progression (PFS2). In Arm A the 9- month PFS was 83%. Rates of grade 3/4 hematologic toxicities included a high incidence of neutropenia, 74% in Arm A and 30% in Arm B; however the rates of febrile neutropenia were low at 8.2% and 6.8% respectively. Grade 3/4 thrombocytopenia were 4.9% and 13.6%, respectively. The most common non-hematologic toxicity was pneumonia in 18% and 16.9% in arms A and B, respectively. Conclusions The results of this randomized phase II trial demonstrate that in a moderately pretreated MM population (median 2 lines of therapy but range 1-8) that the four-drug combination (DCdP) confers impressive response rates (ORR 88.5%) and a 9-month PFS of 83%. Although the three-drug combination (DCd) showed an inferior response rate of 50%, this is superior to Daratumumab used as a single agent in a similar patient population and so far at least 40% of patients who have progressed appear salvageable showing responses upon addition of Pom. Moreover, the addition of low dose cyclophosphamide, an alkylator with recognized immune properties, appears to enhance ORR and produce a durable PFS even when compared to Dara-pom-dex combinations used after two lines of therapy. Toxicities were principally hematologic and few resulted in treatment discontinuations.


  • Data synergy between leaf area index and clumping index Earth Observation products using photon recollision probability theory

    by Jan Pisek, Henning Buddenbaum, Fernando Camacho, Joachim Hill, Jennifer L.R. Jensen, Holger Lange, Zhili Liu, Arndt Piayda, Yonghua Qu, Olivier Roupsard, et al.


  • Open Access

    OPERATIONAL 333m BIOPHYSICAL PRODUCTS OF THE COPERNICUS GLOBAL LAND SERVICE FOR AGRICULTURE MONITORING

    by R. Lacaze, B. Smets, F. Baret, M. Weiss, D. Ramon, B. Montersleet, L. Wandrebeck, J.-C. Calvet, J.-L. Roujean, F. Camacho

    The Copernicus Global Land service provides continuously a set of bio-geophysical variables describing, over the whole globe, the vegetation dynamic, the energy budget at the continental surface and some components of the water cycle. These generic products serve numerous applications including agriculture and food security monitoring. The portfolio of the Copernicus Global Land service contains Essential Climate Variables like the Leaf Area Index (LAI), the Fraction of PAR absorbed by the vegetation (FAPAR), the surface albedo, the Land Surface Temperature, the soil moisture, the burnt areas, the areas of water bodies, and additional vegetation indices. They are generated every hour, every day or every 10 days on a reliable automatic basis from Earth Observation satellite data. Beside this timely production, the available historical archives have been processed, using the same innovative algorithms, to get consistent time series as long as possible. All products are accessible, free of charge after registration through FTP/HTTP (http://land.copernicus.eu/global/) and through the GEONETCast satellite distribution system. The evolution of the service towards the operations at 333m resolution is partly supported by the FP7/ImagineS project which focuses on the retrieval of LAI, FAPAR, fraction of vegetation cover and surface albedo from PROBA-V sensor data. The paper presents the innovations of the 333m biophysical products, make an overview of their current status, and introduce the next steps of the evolution of the Copernicus Global Land service.


  • Open Access

    Retrieving leaf area index from multi-angular airborne data

    by F. J. García-Haro, F. Camacho-De Coca, J. Meliá

    This work is aimed to demonstrate the feasibility of a methodology for retrieving bio-geophysical variables whilst at the same time fully accounting for additional information on directional anisotropy. A model-based approach has been developed to deconvolve the angular reflectance into single landcovers reflectances, attempting to solve the inconsistencies of 1D models and linear mixture approaches. The model combines the geometric optics of large scale canopy structure with principles of radiative transfer for volume scattering within individual crowns. The reliability of the model approach to retrieve LAI has been demonstrated using data from DAISEX- 99 campaign at Barrax, Spain. Airborne data include POLDER and HyMap data in which various field plots were observed under varying viewing/illumination angles. Nearly simultaneously, a comprehensive field data set was acquired on specific crop plots. The inversions provided accurate LAI values, revealing the model potential to combine spectral and directional information to increase the likely accuracy of the retrievals. In addition, the sensitivity of retrievals with the angular and spectral subset of observations was analysed, showing a high consistency between results. This study has contributed to assess the uncertainties with products derived from satellite data like SEVIRI/MSG.